ZK824859
ZK824859 Basic information
- Product Name:
- ZK824859
- Synonyms:
-
- (R)-2-((6-((3'-(Aminomethyl)-5-methyl-[1,1'-biphenyl]-3-yl)oxy)-3,5-difluoropyridin-2-yl)oxy)butanoic acid
- ZK824859,ZK-824859
- Butanoic acid, 2-[[6-[[3'-(aminomethyl)-5-methyl[1,1'-biphenyl]-3-yl]oxy]-3,5-difluoro-2-pyridinyl]oxy]-, (2R)-
- CAS:
- 2271122-53-1
- MF:
- C23H22F2N2O4
- MW:
- 428.43
- Mol File:
- 2271122-53-1.mol
More
Less
ZK824859 Chemical Properties
- Boiling point:
- 542.7±50.0 °C(Predicted)
- Density
- 1.291±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- pka
- 2.62±0.10(Predicted)
More
Less
ZK824859 Usage And Synthesis
Uses
ZK824859 is an oral available and selective urokinase plasminogen activator (uPA) inhibitor with IC50s of 79nM, 1580nM and 1330nM for human uPA, tPA, and plasmin, respectively[1].
in vivo
ZK824859 (50, 25 and 10mg/kg; b.i.d.; 25 days) is used in a chronic mouse EAE model. ZK 824859 completely prevents the development of disease. However, two lower doses (25 and 10mg/kg) have no effect on clinical scores[1].
| Animal Model: | Female SJL mice with chronic mouse EAE model[1] |
| Dosage: | 50, 25 and 10mg/kg |
| Administration: | B.i.d.; 25 days |
| Result: | Prevented the development of disease at 50mg/kg completely. However, 25 and 10mg/kg had no effect on clinical scores. |
References
[1] Islam I, et al. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. Bioorg Med Chem Lett. 2018 Nov 1;28(20):3372-3375. DOI:10.1016/j.bmcl.2018.09.001
ZK824859Supplier
TargetMol Chemicals Inc.
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
Energy Chemical
- Tel
- 021-58432009 400-005-6266
- marketing@energy-chemical.com
TargetMol Chemicals Inc.
- Tel
- 4008200310
- marketing@tsbiochem.com
Adooq Bioscience LLC
- Tel
- 400-025-6535
- sales@adooq.cn
TargetMol Chemicals Inc.
- Tel
- +17819995354
- marketing@targetmol.com